Effect of diet or diet plus physical activity versus usual care on inflammatory markers in patients with newly diagnosed type 2 diabetes: the Early ACTivity in Diabetes (ACTID) randomized, controlled trial
dc.contributor.author | Thompson, D | |
dc.contributor.author | Walhin, J-P | |
dc.contributor.author | Batterham, AM | |
dc.contributor.author | Stokes, KA | |
dc.contributor.author | Cooper, AR | |
dc.contributor.author | Andrews, RC | |
dc.date.accessioned | 2019-01-30T13:16:12Z | |
dc.date.issued | 2014-05-08 | |
dc.description.abstract | BACKGROUND: Inflammation plays a major role in diabetes-associated cardiovascular disease (CVD). There is uncertainty whether diet and physical activity interventions can be successfully integrated into healthcare settings and reduce markers of inflammation and risk of CVD in patients with type 2 diabetes (T2D). METHODS AND RESULTS: Systemic markers of inflammation were determined in a 12-month, real-world, multicenter, randomized, controlled trial that investigated the effect of diet, diet plus physical activity, and usual care in 593 individuals with newly diagnosed T2D. During the first 6 months, serum C-reactive protein (CRP) improved by -21 (-36 to -1.4)% and -22 (-38 to -3.1)% in diet and diet plus physical activity arms versus usual care. There were also improvements in adiponectin and soluble intercellular adhesion molecule-1 (sICAM-1). Though medication-adjusted CRP was improved between 6 and 12 months for usual care, both interventions were more successful in reducing the relative risk of a high-risk CRP level of >3 mg/L (risk ratios of 0.72 [0.55 to 0.95] for diet versus usual care and 0.67 [0.50 to 0.90] for diet plus activity versus usual care). Furthermore, sICAM-1 (a marker of vascular risk), remained substantially lower than usual care in both intervention arms at 12 months. CONCLUSIONS: Motivational, unsupervised diet and/or diet plus physical activity interventions given soon after diagnosis in real-world healthcare settings improve markers of inflammation and cardiovascular risk in patients with T2D, even after accounting for the effect of adjustments to medication to try and control blood pressure, glycated hemoglobin, and lipids. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com/. Unique identifier: ISRCTN92162869. | en_GB |
dc.description.sponsorship | British Heart Foundation | en_GB |
dc.description.sponsorship | Diabetes UK | en_GB |
dc.description.sponsorship | UK Department of Health | en_GB |
dc.identifier.citation | Vol. 3 (3), article e000828 | en_GB |
dc.identifier.doi | 10.1161/JAHA.114.000828 | |
dc.identifier.grantnumber | PG/05/084 | en_GB |
dc.identifier.other | jah3525 | |
dc.identifier.uri | http://hdl.handle.net/10871/35651 | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/24811615 | en_GB |
dc.rights | © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_GB |
dc.subject | cardiovascular disease | en_GB |
dc.subject | exercise | en_GB |
dc.subject | inflammation | en_GB |
dc.subject | physical activity | en_GB |
dc.subject | Adiponectin | en_GB |
dc.subject | Biomarkers | en_GB |
dc.subject | C-Reactive Protein | en_GB |
dc.subject | Cardiovascular Diseases | en_GB |
dc.subject | Combined Modality Therapy | en_GB |
dc.subject | Diabetes Mellitus, Type 2 | en_GB |
dc.subject | Exercise Therapy | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Inflammation | en_GB |
dc.subject | Intercellular Adhesion Molecule-1 | en_GB |
dc.subject | Male | en_GB |
dc.subject | Middle Aged | en_GB |
dc.subject | Motor Activity | en_GB |
dc.title | Effect of diet or diet plus physical activity versus usual care on inflammatory markers in patients with newly diagnosed type 2 diabetes: the Early ACTivity in Diabetes (ACTID) randomized, controlled trial | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2019-01-30T13:16:12Z | |
exeter.place-of-publication | England | en_GB |
dc.description | This is the final version. Available on open access from Wiley via the DOI in this record | en_GB |
dc.identifier.journal | Journal of the American Heart Association | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dcterms.dateAccepted | 2014-03-19 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2014-03-19 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2019-01-30T13:14:08Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2019-01-30T13:16:15Z |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.